Sangamo Therapeutics, Inc. (SGMO)

Market Cap	235.77M
Revenue (ttm)	52.29M
Net Income (ttm)	-134.84M
Shares Out	208.65M
EPS (ttm)	-0.70
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,645,309
Open	1.130
Previous Close	1.090
Day's Range	1.070 - 1.150
52-Week Range	0.300 - 3.180
Beta	1.30
Analysts	Buy
Price Target	5.20 (+360.18%)
Earnings Date	Mar 12, 2025

About SGMO

Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company’s clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of imm...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 6, 2000
• Employees: 405
• Stock Exchange: NASDAQ
• Ticker Symbol: SGMO
• Website: https://www.sangamo.com

Financial Performance

In 2023, Sangamo Therapeutics's revenue was $176.23 million, an increase of 58.34% compared to the previous year's $111.30 million. Losses were -$257.83 million, 34.1% more than in 2022.

Analyst Forecast

According to 5 analysts, the average rating for SGMO stock is "Buy." The 12-month stock price forecast is $5.2, which is an increase of 360.18% from the latest price.

Price Target

$5.2

(360.18% upside)

Analyst Consensus: Buy